Skip to main content

Table 2 Positive rates of 4 tumor markers with single and combined detection in gastric cancer with different stages, location and differentiation

From: Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

  Cases Positive cases (%)
AFP CEA CA125 CA19-9 Qualitative combined
Stage       
early stage 30 1 (3.3) 0 (0.0) 2 (6.7) 2 (6.7) 4 (13.3)
advanced stage 119 6 (5.0) 26 (21.8) 19 (16.0) 29 (24.4) 56 (47.1)
χ 2   0.156 7.940 1.711 4.557 11.330
P   1.000 0.005 0.249 0.042 0.001
Location       
cardia 13 2 (15.4) 5 (38.5) 1 (7.7) 6 (46.2) 9 (69.2)
gastric body 61 0 (0.0) 12 (19.7) 10 (16.4) 7 (11.5) 21 (34.4)
gastric antrum 70 5 (7.1) 9 (12.9) 10 (14.3) 18 (25.7) 30 (42.9)
multi-site 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
χ 2   7.504 6.275 1.529 10.630 8.965
P   0.056 0.098 0.696 0.016 0.026
Differentiation       
high 6 1 (16.7) 1 (16.7) 1 (16.7) 2 (33.3) 3 (50.0)
moderate 72 4 (5.6) 12 (16.7) 8 (11.1) 13 (18.1) 28 (38.9)
poor 71 2 (2.8) 13 (18.3) 12 (16.9) 16 (22.5) 29 (40.8)
χ 2   2.599 0.070 1.024 1.031 0.303
P   0.268 0.930 0.735 0.605 0.839